The explosion in knock-off GLP-1 sales has weakened both of these foundational pillars.
Until federal regulators put an end to this illicit drug trade, both patient safety and the rule of law will remain in needless peril.
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon.
In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its agreement with the drug’s developer, Novo Nordisk.
The case comes a month after Novo terminated its partnership with Hims & Hers, accusing the firm of “fail[ing] to adhere to the law which prohibits mass sales of compounded drugs.”
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The illicit trade in weight-loss drugs deserves a crackdown
Sally C. Pipes
The explosion in knock-off GLP-1 sales has weakened both of these foundational pillars.
Until federal regulators put an end to this illicit drug trade, both patient safety and the rule of law will remain in needless peril.
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon.
In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its agreement with the drug’s developer, Novo Nordisk.
The case comes a month after Novo terminated its partnership with Hims & Hers, accusing the firm of “fail[ing] to adhere to the law which prohibits mass sales of compounded drugs.”
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.